Adlai Nortye Reports Unaudited First Half 2024 Financial Results and Highlights Recent Operational Progress

August 9, 2024

https://www.globenewswire.com/news-release/2024/08/08/2926940/0/en/Adlai-Nortye-Reports-Unaudited-First-Half-2024-Financial-Results-and-Highlights-Recent-Operational-Progress.html

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Aug. 08, 2024 (GLOBE NEWSWIRE) — Adlai Nortye Ltd. (NASDAQ:ANL) (the “Company” or “Adlai Nortye”), a global clinical-stage biotechnology company focused on the development of innovative targeted and immune-modulating cancer therapies, today announced its business highlights, the appointment of Roger Sawhney, M.D. to its Board of Directors and its first half financial results for the period ended June 30, 2024.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.